AFT further broadens R&D pipeline with new product

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





19 January 2024


AFT further broadens R&D pipeline with new product
candidate for Vulva Lichen Sclerosus

AFT Pharmaceuticals (ASX: AFP, NZX: AFT) today announces that it has entered into a
further partnership with one of its long-standing research and development partners,
Belgium’s Hyloris Pharmaceuticals to develop a novel treatment for the management
of the skin condition Vulvar Lichen Sclerosus (VLS) where there is limited availability of
approved treatments.
The medicine (HY-091) comes in the form of a mucosal adhesive patch product and
is based on a known pharmaceutical compound. It also targets an extended duration
of action and a convenient application method that ensures simplicity and
compliance in patients with the disease.
Under the terms of the agreement, AFT and Hyloris will co-invest for the development
of HY-091 for the purpose of registration, approval and worldwide commercialisation.
This collaboration brings together the strengths of Hyloris and AFT, combining strong
internal R&D capabilities and solid expertise in clinical trial management.
AFT Managing Director Dr Hartley Atkinson says: “This additional collaboration
combines the strengths of AFT and Hyloris and leverages our current Maxigesic
®
IV and
Burning Mouth Syndrome R&D partnerships. I look forward realising the success and
growth potential the medicine offers our companies and importantly assists our
combined international expansion goals."
“We had previously flagged to the market at our announcement of 22 December
2023 that we were targeting further increasing our R&D pipeline with three projects
under diligence. This was one of those projects, and we confirm that we are still
working to complete diligence on a further two projects. We continue to pursue an
expansion of the R&D pipeline recognising that these projects underpin our aspirations
for long-term global expansion,” said Dr Atkinson.
VLS
1,2,3
is a chronic, distressing, inflammatory disease with an enormous impact on
quality of life. HY-091 is designed as a user-friendly mucoadhesive film product for
patients experiencing the discomfort, itching, and pain associated with VLS .

There is no curative treatment for VLS, which usually occurs in postmenopausal
women, although children and premenopausal women may be affected. Advanced
disease severely affects the quality of life and is associated with increased risk

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

of vulvar squamous cell carcinoma. It is a hugely under diagnosed condition, which
affects 0.1% to 3% of the general population.

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief
Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter, prescription, and hospital.
AFT Pharmaceutical's product portfolio comprises both proprietary and in -licensed
products, and includes patented, branded, and generic drugs.

1
https://www.uptodate.com/contents/vulvar-lichen-sclerosus-beyond-the-basics
2
https://www.jogc.com/article/S1701-2163(21)00890-2/fulltext
3
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496281/